Pemphigus Vulgaris Successfully Treated With Bromocriptine
We describe a case of PV successfully treated with nonconventional treatment, bromocriptine mesylate. Bromocriptine has been used in human trials showing beneficial therapeutic effects in managing autoimmune conditions. The results from experimental trials and the low toxicity of bromocriptine in comparison with immunosuppressive agents form a solid rationale for investigating its role in controlling PV. J Drugs Dermatol. 2024;23(3): doi:10.36849/JDD.7720e.PMID:38443120 | DOI:10.36849/jdd.7220 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - March 5, 2024 Category: Dermatology Authors: Natalya Lyadova Narmin S Ghalichi Source Type: research
Comparing Clinical Outcomes of Steroid-Sparing Therapy With Rituximab Versus Rituximab Alone in Pemphigus
CONCLUSIONS: The use of SST with rituximab dosing did not improve clinical outcomes related to time to remission, reduction in prednisone dosing, or relapse. These data provide further evidence for the use of rituximab in the majority of pemphigus patients without the need for SST. J Drugs Dermatol. 2024;23(3):e97-e99 doi:10.36849/JDD.7949e.PMID:38443121 | DOI:10.36849/jdd.7949 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - March 5, 2024 Category: Dermatology Authors: Danielle E Mustin Emily F Cole Rebecca Leibowitz Ron J Feldman Source Type: research
Pemphigus Vulgaris Successfully Treated With Bromocriptine
We describe a case of PV successfully treated with nonconventional treatment, bromocriptine mesylate. Bromocriptine has been used in human trials showing beneficial therapeutic effects in managing autoimmune conditions. The results from experimental trials and the low toxicity of bromocriptine in comparison with immunosuppressive agents form a solid rationale for investigating its role in controlling PV. J Drugs Dermatol. 2024;23(3): doi:10.36849/JDD.7720e.PMID:38443120 | DOI:10.36849/jdd.7220 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - March 5, 2024 Category: Dermatology Authors: Natalya Lyadova Narmin S Ghalichi Source Type: research
Comparing Clinical Outcomes of Steroid-Sparing Therapy With Rituximab Versus Rituximab Alone in Pemphigus
CONCLUSIONS: The use of SST with rituximab dosing did not improve clinical outcomes related to time to remission, reduction in prednisone dosing, or relapse. These data provide further evidence for the use of rituximab in the majority of pemphigus patients without the need for SST. J Drugs Dermatol. 2024;23(3):e97-e99 doi:10.36849/JDD.7949e.PMID:38443121 | DOI:10.36849/jdd.7949 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - March 5, 2024 Category: Dermatology Authors: Danielle E Mustin Emily F Cole Rebecca Leibowitz Ron J Feldman Source Type: research
Pemphigus Vulgaris Successfully Treated With Bromocriptine
We describe a case of PV successfully treated with nonconventional treatment, bromocriptine mesylate. Bromocriptine has been used in human trials showing beneficial therapeutic effects in managing autoimmune conditions. The results from experimental trials and the low toxicity of bromocriptine in comparison with immunosuppressive agents form a solid rationale for investigating its role in controlling PV. J Drugs Dermatol. 2024;23(3): doi:10.36849/JDD.7720e.PMID:38443120 | DOI:10.36849/jdd.7220 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - March 5, 2024 Category: Dermatology Authors: Natalya Lyadova Narmin S Ghalichi Source Type: research
Comparing Clinical Outcomes of Steroid-Sparing Therapy With Rituximab Versus Rituximab Alone in Pemphigus
CONCLUSIONS: The use of SST with rituximab dosing did not improve clinical outcomes related to time to remission, reduction in prednisone dosing, or relapse. These data provide further evidence for the use of rituximab in the majority of pemphigus patients without the need for SST. J Drugs Dermatol. 2024;23(3):e97-e99 doi:10.36849/JDD.7949e.PMID:38443121 | DOI:10.36849/jdd.7949 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - March 5, 2024 Category: Dermatology Authors: Danielle E Mustin Emily F Cole Rebecca Leibowitz Ron J Feldman Source Type: research
Pemphigus Vulgaris Successfully Treated With Bromocriptine
We describe a case of PV successfully treated with nonconventional treatment, bromocriptine mesylate. Bromocriptine has been used in human trials showing beneficial therapeutic effects in managing autoimmune conditions. The results from experimental trials and the low toxicity of bromocriptine in comparison with immunosuppressive agents form a solid rationale for investigating its role in controlling PV. J Drugs Dermatol. 2024;23(3): doi:10.36849/JDD.7720e.PMID:38443120 | DOI:10.36849/jdd.7220 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - March 5, 2024 Category: Dermatology Authors: Natalya Lyadova Narmin S Ghalichi Source Type: research
Comparing Clinical Outcomes of Steroid-Sparing Therapy With Rituximab Versus Rituximab Alone in Pemphigus
CONCLUSIONS: The use of SST with rituximab dosing did not improve clinical outcomes related to time to remission, reduction in prednisone dosing, or relapse. These data provide further evidence for the use of rituximab in the majority of pemphigus patients without the need for SST. J Drugs Dermatol. 2024;23(3):e97-e99 doi:10.36849/JDD.7949e.PMID:38443121 | DOI:10.36849/jdd.7949 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - March 5, 2024 Category: Dermatology Authors: Danielle E Mustin Emily F Cole Rebecca Leibowitz Ron J Feldman Source Type: research
Pemphigus Vulgaris Successfully Treated With Bromocriptine
We describe a case of PV successfully treated with nonconventional treatment, bromocriptine mesylate. Bromocriptine has been used in human trials showing beneficial therapeutic effects in managing autoimmune conditions. The results from experimental trials and the low toxicity of bromocriptine in comparison with immunosuppressive agents form a solid rationale for investigating its role in controlling PV. J Drugs Dermatol. 2024;23(3): doi:10.36849/JDD.7720e.PMID:38443120 | DOI:10.36849/jdd.7220 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - March 5, 2024 Category: Dermatology Authors: Natalya Lyadova Narmin S Ghalichi Source Type: research
Comparing Clinical Outcomes of Steroid-Sparing Therapy With Rituximab Versus Rituximab Alone in Pemphigus
CONCLUSIONS: The use of SST with rituximab dosing did not improve clinical outcomes related to time to remission, reduction in prednisone dosing, or relapse. These data provide further evidence for the use of rituximab in the majority of pemphigus patients without the need for SST. J Drugs Dermatol. 2024;23(3):e97-e99 doi:10.36849/JDD.7949e.PMID:38443121 | DOI:10.36849/jdd.7949 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - March 5, 2024 Category: Dermatology Authors: Danielle E Mustin Emily F Cole Rebecca Leibowitz Ron J Feldman Source Type: research
Pemphigus Vulgaris Successfully Treated With Bromocriptine
We describe a case of PV successfully treated with nonconventional treatment, bromocriptine mesylate. Bromocriptine has been used in human trials showing beneficial therapeutic effects in managing autoimmune conditions. The results from experimental trials and the low toxicity of bromocriptine in comparison with immunosuppressive agents form a solid rationale for investigating its role in controlling PV. J Drugs Dermatol. 2024;23(3): doi:10.36849/JDD.7720e.PMID:38443120 | DOI:10.36849/jdd.7220 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - March 5, 2024 Category: Dermatology Authors: Natalya Lyadova Narmin S Ghalichi Source Type: research
Comparing Clinical Outcomes of Steroid-Sparing Therapy With Rituximab Versus Rituximab Alone in Pemphigus
CONCLUSIONS: The use of SST with rituximab dosing did not improve clinical outcomes related to time to remission, reduction in prednisone dosing, or relapse. These data provide further evidence for the use of rituximab in the majority of pemphigus patients without the need for SST. J Drugs Dermatol. 2024;23(3):e97-e99 doi:10.36849/JDD.7949e.PMID:38443121 | DOI:10.36849/jdd.7949 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - March 5, 2024 Category: Dermatology Authors: Danielle E Mustin Emily F Cole Rebecca Leibowitz Ron J Feldman Source Type: research
